<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Estrella Immunopharma Inc. — News on 6ix</title>
<link>https://6ix.com/company/estrella-immunopharma-inc</link>
<description>Latest news and press releases for Estrella Immunopharma Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 23 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/estrella-immunopharma-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835646078dffbe2df0efa3f.webp</url>
<title>Estrella Immunopharma Inc.</title>
<link>https://6ix.com/company/estrella-immunopharma-inc</link>
</image>
<item>
<title>Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research</title>
<link>https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-inc-nasdaq-esla-receives-initiating-coverage-with-a-valuation-of-dollar1200share-from-zacks-small-cap-research</link>
<guid isPermaLink="true">https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-inc-nasdaq-esla-receives-initiating-coverage-with-a-valuation-of-dollar1200share-from-zacks-small-cap-research</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®</title>
<link>https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-presents-promising-updated-120000396</link>
<guid isPermaLink="true">https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-presents-promising-updated-120000396</guid>
<pubDate>Mon, 09 Feb 2026 12:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., February 09, 2026--Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research).</description>
</item>
<item>
<title>Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®</title>
<link>https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-announces-breaking-oral-130000661</link>
<guid isPermaLink="true">https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-announces-breaking-oral-130000661</guid>
<pubDate>Tue, 03 Feb 2026 13:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., February 03, 2026--Estrella Immunopharma, Inc. (Nasdaq: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced its STARLIGHT-1 phase I result will be orally presented at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research).</description>
</item>
<item>
<title>Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement</title>
<link>https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-announces-closing-8-190200212</link>
<guid isPermaLink="true">https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-announces-closing-8-190200212</guid>
<pubDate>Tue, 06 Jan 2026 19:02:00 GMT</pubDate>
<description>EMERYVILLE, Calif., January 06, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced the closing of its previously announced registered direct offering, with a single healthcare-focused institutional investor, for the issuance and sale of 4,063,290 shares of the Company’s common stock and 1,000,000 pre-funded warrants.</description>
</item>
<item>
<title>Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-inc-announces-8-133000343</link>
<guid isPermaLink="true">https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-inc-announces-8-133000343</guid>
<pubDate>Mon, 05 Jan 2026 13:30:00 GMT</pubDate>
<description>EMERYVILLE, Calif., January 05, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced that it has entered into definitive agreements with a single healthcare-focused institutional investor for the purchase and sale of shares of common stock, par value $0.0001 per share ("Common Stock") and pre-funded warrants (the "Pre-Funded</description>
</item>
<item>
<title>Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation</title>
<link>https://6ix.com/company/estrella-immunopharma-inc/news/estrella-advances-starlight-1-trial-130000482</link>
<guid isPermaLink="true">https://6ix.com/company/estrella-immunopharma-inc/news/estrella-advances-starlight-1-trial-130000482</guid>
<pubDate>Thu, 04 Dec 2025 13:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., December 04, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its review of safety data from the Phase I dose escalation portion of the STARLIGHT-1 trial. Based on the favorable safety profile observed, the DSMB recomme</description>
</item>
<item>
<title>Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients</title>
<link>https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-completes-second-dose-130000781</link>
<guid isPermaLink="true">https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-completes-second-dose-130000781</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., November 03, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the successful completion of the second dose cohort in Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103, a CD19-redirected ARTEMIS® T-cell therapy to treat patients with Advanced B-Cell Non-Hodgkin’s Lympho</description>
</item>
<item>
<title>Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements</title>
<link>https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-regains-compliance-nasdaq-120000043</link>
<guid isPermaLink="true">https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-regains-compliance-nasdaq-120000043</guid>
<pubDate>Mon, 06 Oct 2025 12:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., October 06, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, announces that, as previously disclosed in its Current Report on Form 8-K filed on September 29, 2025, the Company has regained compliance with the listing requirements of The Nasdaq Stock Market LLC ("Nasdaq"). This confirmation follows the Co</description>
</item>
<item>
<title>Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma</title>
<link>https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-announces-activation-additional-120000617</link>
<guid isPermaLink="true">https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-announces-activation-additional-120000617</guid>
<pubDate>Thu, 05 Jun 2025 12:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., June 05, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL)</description>
</item>
<item>
<title>Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing</title>
<link>https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-announces-approximately-3-120000927</link>
<guid isPermaLink="true">https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-announces-approximately-3-120000927</guid>
<pubDate>Tue, 03 Jun 2025 12:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., June 03, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that on May 30, 2025, it entered into a securities purchase agreement (the "Purchase Agreement") for a private investment in public equity ("PIPE") financing that is expected to result in approximately $3.35 million in gross procee</description>
</item>
<item>
<title>Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas</title>
<link>https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-initiates-second-cohort-120100624</link>
<guid isPermaLink="true">https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-initiates-second-cohort-120100624</guid>
<pubDate>Thu, 29 May 2025 12:01:00 GMT</pubDate>
<description>EMERYVILLE, Calif., May 29, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been dosed in the second cohort of its dose escalation study of Phase I/II STARLIGHT-1 trial for EB103, a CD19-redirected ARTEMIS® T-cell therapy to treat patients with Advanced B-Cell Non-Hodgkin’s Lympho</description>
</item>
<item>
<title>Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort</title>
<link>https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-completes-first-dose-133000768</link>
<guid isPermaLink="true">https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-completes-first-dose-133000768</guid>
<pubDate>Fri, 21 Feb 2025 13:30:00 GMT</pubDate>
<description>EMERYVILLE, Calif., February 21, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the successful completion of the first dose cohort in its ongoing STARLIGHT-1 Phase I/II clinical trial. Following a review of safety and efficacy data, the Data and Safety Monitoring Board (DSMB) has approved the initiation of t</description>
</item>
<item>
<title>Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells</title>
<link>https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-achieves-complete-response-in-first-patient-treated-with-cd19-redirected-artemisr-t-cells</link>
<guid isPermaLink="true">https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-achieves-complete-response-in-first-patient-treated-with-cd19-redirected-artemisr-t-cells</guid>
<pubDate>Fri, 27 Sep 2024 04:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical</description>
</item>
<item>
<title>Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member</title>
<link>https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-announces-appointment-of-hong-zhang-as-chairperson-and-board-member</link>
<guid isPermaLink="true">https://6ix.com/company/estrella-immunopharma-inc/news/estrella-immunopharma-announces-appointment-of-hong-zhang-as-chairperson-and-board-member</guid>
<pubDate>Wed, 14 Aug 2024 04:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) ("Estrella", “Estrella Immunopharma”, or the "Company"), a clinical</description>
</item>
</channel>
</rss>